[DOI] [PubMed] [Google Scholar] 93.Schltzer-Schrehardt U., Zenkel M., Strunz M., Giel A., Schondorf H., da Silva H., Schmidt G.A., Greiner M.A., Okumura N., Koizumi N., et al
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial Summary: This Phase 1b trial assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of co-administering once-weekly subcutaneous cagrilintide (at various doses) with semaglutide 2.4 mg in participants for weight management
Switch to the ventrogluteal site for repeated dosing or clients with limited deltoid mass
351 (2): p